Scoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression
Daniel Toro-Domínguez, Jordi Martorell-Marugán, Manuel Martinez-Bueno, Raúl López-Domínguez, Elena Carnero-Montoro, Guillermo Barturen, Daniel Goldman, Michelle Petri, Pedro Carmona-Sáez, Marta E Alarcón-Riquelme, Daniel Toro-Domínguez, Jordi Martorell-Marugán, Manuel Martinez-Bueno, Raúl López-Domínguez, Elena Carnero-Montoro, Guillermo Barturen, Daniel Goldman, Michelle Petri, Pedro Carmona-Sáez, Marta E Alarcón-Riquelme
Abstract
Objectives: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to significant worsening of quality of life and mortality. Flares appear unpredictably during the disease course and therapies used are often only partially effective. These challenges are mainly due to the molecular heterogeneity of the disease, and in this context, personalized medicine-based approaches offer major promise. With this work we intended to advance in that direction by developing MyPROSLE, an omic-based analytical workflow for measuring the molecular portrait of individual patients to support clinicians in their therapeutic decisions.
Methods: Immunological gene-modules were used to represent the transcriptome of the patients. A dysregulation score for each gene-module was calculated at the patient level based on averaged z-scores. Almost 6100 Lupus and 750 healthy samples were used to analyze the association among dysregulation scores, clinical manifestations, prognosis, flare and remission events and response to Tabalumab. Machine learning-based classification models were built to predict around 100 different clinical parameters based on personalized dysregulation scores.
Results: MyPROSLE allows to molecularly summarize patients in 206 gene-modules, clustered into nine main lupus signatures. The combination of these modules revealed highly differentiated pathological mechanisms. We found that the dysregulation of certain gene-modules is strongly associated with specific clinical manifestations, the occurrence of relapses or the presence of long-term remission and drug response. Therefore, MyPROSLE may be used to accurately predict these clinical outcomes.
Conclusions: MyPROSLE (https://myprosle.genyo.es) allows molecular characterization of individual Lupus patients and it extracts key molecular information to support more precise therapeutic decisions.
Trial registration: ClinicalTrials.gov NCT01205438 NCT01196091.
Keywords: Systemic Lupus Erythematosus; autoimmune diseases; computational models; molecular profiling; personalized medicine.
© The Author(s) 2022. Published by Oxford University Press.
Figures
References
- Goldblatt F, O’Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet Lond Engl 2013;382:797–808.
- Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov 2018;17:197–223.
- Casey KA, Smith MA, Sinibaldi D, et al. . Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus. Arthritis Rheumatol 2021;73:459–71.
- Allen ME, Rus V, Szeto GL. Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. Trends Mol Med 2021;27:152–71.
- Chasset F, Arnaud L. Targeting interferons and their pathways in systemic lupus erythematosus. Autoimmun Rev 2018;17:44–52.
- Bombardier C, Gladman DD, Urowitz MB, et al. . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–40.
- Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res 2011;63(Suppl 11):S37–46.
- Sicklick JK, Kato S, Okamura R, et al. . Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med 2019;25:744–50.
- Madani Tonekaboni SA, Beri G, Haibe-Kains B. Pathway-Based Drug Response Prediction Using Similarity Identification in Gene Expression. Front Genet 2020;11:1016.
- Franco M, Jeggari A, Peuget S, et al. . Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data. Sci Rep 2019;9:2379.
- Tavakolpour S. Towards personalized medicine for patients with autoimmune diseases: Opportunities and challenges. Immunol Lett 2017;190:130–8.
- Barturen G, Babaei S, Català-Moll F, et al. . Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. Arthritis Rheumatol 2021;73:1073–1085.
- Lewis MJ, Barnes MR, Blighe K, et al. . Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. Cell Rep 2019;28:2455–2470.e5.
- Banchereau R, Hong S, Cantarel B, et al. . Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell 2016;165:551–65.
- Toro-Domínguez D, Martorell-Marugán J, Goldman D, et al. . Stratification of Systemic Lupus Erythematosus Patients Into Three Groups of Disease Activity Progression According to Longitudinal Gene Expression. Arthritis Rheumatol Hoboken NJ 2018;70:2025–35.
- Guthridge JM, Lu R, Tran LT-H, et al. . Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study. EClinicalMedicine 2020;20(100291):100291.
- Díaz-Peña R. Personalized Medicine in Autoimmune Diseases. J Pers Med 2021;11:1181.
- Yu H, Nagafuchi Y, Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules 2021;11:928.
- Clough E, Barrett T. The Gene Expression Omnibus database. Methods Mol Biol Clifton NJ 2016;1418:93–110.
- Hoffman RW, Merrill JT, Alarcón-Riquelme MME, et al. . Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. Arthritis Rheumatol Hoboken NJ 2017;69:643–54.
- Martorell-Marugán J, López-Domínguez R, García-Moreno A, et al. . A comprehensive database for integrated analysis of omics data in autoimmune diseases. BMC Bioinformatics 2021;22:343.
- Wing MKC from J , Weston S, Williams A, et al.caret: Classification and Regression Training. 2019; .
- Li S, Rouphael N, Duraisingham S, et al. . Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 2014;15:195–204.
- Chaussabel D, Quinn C, Shen J, et al. . A Modular Analysis Framework for Blood Genomics Studies: Application to Systemic Lupus Erythematosus. Immunity 2008;29:150–64.
- Weiner J, Domaszewska T. tmod: an R package for general and multivariate enrichment analysis. PeerJ Preprints, 2016;4:e2420v.
- Menche J, Guney E, Sharma A, et al. . Integrating personalized gene expression profiles into predictive disease-associated gene pools. Npj Syst Biol Appl 2017;3:1–10.
- Bolaños AB. Probability & Statistical Concepts: an Introduction 1977.
- Wang B, Mezlini A, Demir F, et al. . SNFtool: Similarity Network Fusion. 2021.
- Charrad M, Ghazzali N, Boiteau V, et al. . NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set. J Stat Softw 2014;61:1–36.
- Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010;26:1572–3.
- Larner AJ. Accuracy of cognitive screening instruments reconsidered: overall, balanced or unbiased accuracy? Neurodegener. Dis Manag 2022;12:67–76.
- Luijten KM a C, Tekstra J, JWJ B, et al. . The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2012;11:326–9.
- Ritchie ME, Phipson B, Wu D, et al. . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.
- Vremec D, O’Keeffe M, Hochrein H, et al. . Production of interferons by dendritic cells, plasmacytoid cells, natural killer cells, and interferon-producing killer dendritic cells. Blood 2007;109:1165–73.
- Rönnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med 2019;6:e000270.
- Davidson A. Targeting BAFF in autoimmunity. Curr Opin Immunol 2010;22:732–9.
- Chang W, Cheng J, Allaire JJ, et al. . shiny: Web Application Framework for R. 2021.
- Nishi H, Mayadas TN. Neutrophils in lupus nephritis. Curr Opin Rheumatol 2019;31:193–200.
- Jourde-Chiche N, Whalen E, Gondouin B, et al. . Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. Rheumatology 2017;56:477–87.
- Rovin BH, Parikh S, Alvarado A. The Kidney Biopsy in Lupus Nephritis: Is it Still Relevant? Rheum Dis Clin North Am 2014;40:537–52.
- Bauer JW, Baechler EC, Petri M, et al. . Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006;3:e491.
- Andrade S d O, Julio PR, Nunes de Paula Ferreira D, et al. . Predicting lupus flares: epidemiological and disease related risk factors. Expert Rev. Clin Immunol 2021;17:143–53.
- Crow MK, Type I. Interferon in the Pathogenesis of Lupus. J Immunol Baltim Md 1950;192(192):5459–68.
- Isenberg DA, Petri M, Kalunian K, et al. . Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:323–31.
- Petri M, Fu W, Ranger A, et al. . Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. BMC Med Genomics 2019;12:4.
- Hung T, Pratt GA, Sundararaman B, et al. . The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression. Science 2015;350:455–9.
- Hu Y, Carman JA, Holloway D, et al. . Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. Arthritis Rheumatol. Hoboken NJ 2018;70:1331–42.
Source: PubMed